Track topics on Twitter Track topics that are important to you
Wednesday, October 19th 2016 at 11:20am UTC STOCKHOLM, Sweden–(BUSINESS WIRE)– Swedish Orphan Biovitrum AB (publ) (http://www.sobi.com/) (Sobi™) (STO: SOBI) has been granted orphan designation by the European Commission (EC) for the company’s development product candidate SOBI003, a chemically modified human recombinant sulfamidase for the treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome). SOBI003 will be included …
Cet article Swedish Orphan Biovitrum AB: European Commission Grants SOBI003 Orphan
Designation for the Treatment of MPS IIIA est apparu en premier sur EEI-BIOTECHFINANCES.
Recombinant DNA is the formation of a novel DNA sequence by the formation of two DNA strands. These are taken from two different organisms. These recombinant DNA molecules can be made with recombinant DNA technology. The procedure is to cut the DNA of ...